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Normal human  serum inhibits  the  activity of  C'I  esterase  (C'lsa),  an  enzyme 
derived from the  Cqs fragment of the first component of complement (Cq)  (1-3). 
This inhibitory property has been localized to a heat-labile a2-globulin, distinct from 
serum antitrypsin, designated variously as C'I esterase inhibitor,  C'la inhibitor,  or 
EI (4). Donaldson and Evans (5) reported that the serum of patients with hereditary 
anga'oneurotic edema behaved as if it lacked functional Cq  esterase inhibitor. Inde- 
pendently, Landerman and his associates  (6)  observed that in this disorder  serum 
lacked inhibitory activity against a plasma knnlkrein or against PF/Dil (a factor in 
human plasma which increases  cutaneous vascular permeability), or against both of 
these substances. Kagan and Becker (7, 8) unified these two studies by demonstrating 
that preparations rich in C'I esterase inhibitor blocked the effects of plasma kallikrein 
and PF/Dil.  Their experiments suggested  that Cq  esterase inhibitor might possess 
several biological functions. 
The preparations of Cq esterase inhibitor used by Kagan and Becker were 
relatively crude  (7).  The properties of  this  inhibitor  have been  reexamined, 
using  more  purified  preparations.  The  capacity of  C~I  esterase  inhibitor  to 
block the actions of a  plasma kallikrein and of PF/Dil have been confirmed. 
Moreover,  Cq  esterase  inhibitor,  at  concentrations  comparable  to  those  in 
normal human plasma, has been found to inhibit plasmin and  the Cqr frag- 
ment of Cq. Thus,  the agent designated as Cq  esterase inhibitor appears to 
be a  more  generalized  inhibitor  of hydrolytic  enzymes  than  had  heretofore 
been appreciated. 
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Materials and Methods 
C'1 e.sterase inhibitor was purified from human  serum by a modification of a method de- 
scribed  earlier  (4).  Briefly, the method  consisted  of adding  ammonium  sulfate  to  human 
serum to 40% ~turafion,  sedimenting the insoluble protein, and dialyzing the supematant 
solution exhaustively against distilled water. The dialyzed supematant fraction was passed 
through a column of Dowex 2-X10 and protein containing Cq esterase inhibitor activity was 
elated  by  stepwise increases of sodium  chloride  concentration  (3).  Fractions  rich  in  C'I 
esterase inhibitor were pooled, concentrated by pressure dialysis, and applied to a column of 
DEAE cellulose (Whatman  DE-52)  equilibrated with 0.06  ~  tris  (hydroxymethyl)  amino- 
methane  (Tris)-chloride buffer,  pH 8.6.  A concentration graxlient  of sodium chloride, linear 
from zero to 0.15 ~r was passed through the column and fractions richest in Cq esterase in- 
hibitor were  again pooled, concentrated,  dialyzed  against  0.005  M  phosphate  buffer,  and 
applied to a column of hydroxylapatite equilibrated with the same buffer. The C'I esterase 
inhibitor emerged at the void volume of the column and fractions of highest specific activity 
were pooled and recycled through a  second hydroxytapatite colunm. The final product had 
an activity of approximately 200 C'I esterase inhibitor units per optical density unit at 280 
m/z and gave a single,  broad band in analytical disc gel electrophoresis (9).  One unit of in- 
hibitor corresponded to approximately 12/zg of protein. The inhibitor was dissolved in 0.005 
phosphate  buffer. One unit of C'I esterase inhibitor is that  amount which neutralizes the 
esterolytic properties of 10 units of Cq esterase, as as~yed upon a substrate of N-acetyl-L- 
tyrosine ethyl ester (2). 
Plate~clefld~  ¢~rate.d plasma  was prepared  from  the venous blood  of normal human 
subjects in such a way that it was protected from contact with glass or other ciot-promoting 
surfaces (10). One-nlnth volume of sodium citrate buffer (pH 5.0, 0.13 ~  with respect to cit- 
rate) was added to the blood as an anticoagulant. 
Column-pu~f~,¢l bo~  t~ombin, devoid of detectable Stuart  f~tor  (factor X), was pre- 
pared from Topical Thrombin  (Parke,  Davis and Co., Detroit, Mich.) by a modification of 
Rasmu~en's (11) method and stored at -20°(2 in 1% bovine albumin in barbital saline buf- 
fer (12). Just before use, the thrombin was assayed by compafin~ its procoagulant activity 
with that of untreated Topical Thrombin. Plasminog~-poor  b~  thrombin was prepared by 
treating Topical Thrombin with 2-mercaptoethanolamine  (Nutritional Biochemicals Corp., 
Cleveland, Ohio) by the method of Markus and Ambrus (13), stored at -20°C, and diluted 
in barbital saline buffer to the concentration desired before use. 
Partially  purified plasminogen was prepared  from Cohn fraction III4 of human plasma  1 
by a  method described elsewhere (14). The batch used contained 8.8 Remmert and  Cohen 
units of pla*minogen per milligram of protein; about 10% was in the form of plasmin. This 
preparation,  dissolved at a concentration of 7.2 Remmert and  Cohen units per millih'ter of 
0.15 ~t sodium phosphate buffer (pH 7.5) was used as a source of spontaneously acffvated human 
plasmin.  A  second human plasminogen preparation,  separated  in a  different way (15),  pro- 
vided another source of spontaneously activated plasmin,  x This preparation was diluted  in 
0.15 M sodium phosphate buffer to provide a plasmin concentration of 1.3 Remmert and Cohen 
unit per milliliter. Streptoldnase.-activate~ human plasmin,  ~ containing 130 Merck, Sharp and 
Dohme (MS])) units per milligram, was dissolved in distilled water at a concentration of 20 
mg/ml and diluted as needed. 
Bovine f~rinogen  (Cohu fraction I, Armour Pharmaceutical Co., Kankakee, Ill.) containing 
approximately 50~  sodium citrate, was dissolved at 37°C  at a  concentration of 4  mg dry 
weight/ml in barbital saline buffer and faltered through Whatman No. 1 paper. 
1 The gift of Cutter Laboratories, Berkeley, Calif. 
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Partially purified human fibrlnogvn, prepared as fraction I-O by the method of Blomb~ck 
and Blomb~ck  (16), was dissolved in a solution cont~;n;ng 0.45 g sodium chloride and 2.0 
g sodium citrate in 100 ml of water. 
Fibrin plates (17) were prepared by clotting 10 ml of 0.2% human fibrinogen with 0.5 ml 
bovine thrombin (20 NIH units/ml) in a 9 cm disposable plastic Petri dish. The fibrinogen 
used to prepared these plates was separated by the technique of Bergstrom (18) in which Cohn 
fraction I  is precipitated in the presence of epsilon ~mlnocaproic add.  z The fibrinogen was 
dissolved in barbital saline buffer at a concentration of 200 rag/100 ml. 
Urokinase,  a cont~;n;ng  2200 CTA units/rag, was dissolved at a concentration of 1000 CTA 
uults/ml of phosphate  saline buffer. 
C'lr and C'ls were separated from the euglobulin  fraction of human serum by chromatog- 
raphy upon columns of diethylaminoethyl cellulose,  as described earlier (3).  Fractions con- 
taining C'lr and C'ls were pooled  and dialyzed against sodium phosphate buffer (pH 7.4, 
ionic strength 0.15) and stored at 2°C until needed. To designate their concentrations, the 
C'lr and C'ls activities of the dialyzed pools will be described as "undiluted." 
N-acetyl-L-arginine methyl ester hydroctdoride (AAME; Cyclo Chemical Corp., Los Angeles, 
Calif.) dried by extraction with ether, and N-~-acetyl-~lysine methyl ester hydrocldoride 
(ALME, Cyclo Chemical Corp.) were dissolved at a concentration of 0.015 ~  in phosphate 
saline buffer; the N-acetyl-~arginine methyl ester solution was adjusted to pH 7.4 by the 
addition of 0.15 ~  sodium hydroxide. N-aoetyl-z-tyro~ine ethyl ester (ALTEE) synthesized by 
Dr. F. M. Bumpus, the Cleveland Clinic, was dissolved at a concentration of 1 ~in 2-methoxy- 
ethanol (Methyl Cellosolve, Eastman Organic Chemicals, Inc., Rochester, N. Y.) 
FJ/ag/c add, synthesized by Dr. J. D. Crum (see reference  19) or purchased in cruder form 
from K. and K. Laboratories, Inc., Plainview, N. Y., was dissolved at a concentration  of 0.0001 
M in barbital saline buffer, aided by mechanical  homogenization, and used without centrifuga- 
tion. 
Casein (I:l~mmersten quality, Nutritional Biochemicals Corp.), was prepared as a  1.6% 
solution in 0.15 ~ sodium phosphate buffer (pH 7.5) by a modification of the method of Mul- 
lertz (20). 
Kaolin  (acid-washed,  N.F., Fisher Scientific Co., Pittsburgh, Pa.) was suspended at a con- 
centration of 8 mg/ml in sodium acetate buffer (pH 4.8, 0.01 g  with respect to acetate) by 
mechanical homogenization. 
L/quo/d  (sodium polyanetholsulfonate)  4 was dissolved  at a concentration of 0.066 mg/ml 
in sodium phosphate buffer (pH 7.4, ionic strength 1.07). 
Barbital sa~ine buffer was composed of 0.025 ~r barbital and 0.125 ~r sodium chloride at pH 
7.5  (10).  Phosphate  saNne buffer was 0.067 g  sodium phosphate  (pH 7.4)  in 0.6% sodium 
chloride. Phosphate buffer, 0.005 ~,was the sodium salt at pH 6.7. Other buffers used are noted 
in the text. 
Formaldehyde solution (38%, Fisher Scientific Co.) was rendered slightly pink to phenolph- 
thalein by the addition of 1 N sodium hydroxide. 
Celite duate was prepared  essentially by the method  of Nossel  (21)  in which citrated 
plasma, at pH 7.4, was adsorbed with diatomaceous earth (Celite 512).  5 The celite was washed 
with twice the original plasma volume of 0.15 M sodium chloride and eluted with a volume 
of 10% sodium chloride in 0.05 ~s Tris (pH 8.0)  equal to that of the original plasma. The 
eluate was a rich source of plasma kallikrein but also contained plasma thromboplastin ante- 
cedent (I~A, factor XI), small amounts of thrombin and probably kallikreinogen and Hage- 
man factor  (factor XII). It was dialyzed against phosphate saline buffer before use. 
a The gift of Abbott Laboratories, North Chicago,  Ill. 
4 The gift of Hoffmann LaRoche Laboratories, Nutley, N. J. 
6 The  gift  of Johns-Manville Celite Division, Cleveland, Ohio. 318  SERUM  ctl  ESTERASE  INI:LLt~ITOR 
Crude proM~nin was separated from normal human plasma by a modification of a  previ- 
ously described technique (14).  Plasma,  depleted of antihemophilic factor and some of its 
fibrinogen by cryoprecipitation, was adsorbed with one-one hundredth volume of alumina 
C'y-gel (Calbiochem, Los Angeles, Calif.) to remove the vitamin K-dependent clotting factors. 
The fraction soluble at one-third saturation but insoluble at half-saturation with solid am- 
monium sulfate was dialyzed against 0.01 g  sodium acetate  (pH 5.2). The precipitate was 
separated  by centrifugation and discarded.  The supernatant fraction was dialyzed  against 
barbital saline buffer, heated at 62°C  for 30 rain to inactivate any Hageman factor or kalli- 
kreinogen which may still have been present, recentrifuged, and the supematant fluid, con- 
t~inlng prok;nln, stored at  -20°C  until needed. 
Hexadimethrine brom/de  s was dissolved in barbital saline buffer at a concentration of 1 mg/ 
ml  and used  at  this concentration. 
O-phenantl~roline (Fisher Scientific Co.) was dissolved at a concentration of 0.01  g  in bar- 
bital saline buffer. 
The effect of C'I esterase inhibitor  upon the clotting time of whole blood was tested by a three 
tube  technique described  earlier  (22).  0.9  ml  of  venous blood,  freshly drawn  through an 
18 gauge needle into a  polypropylene syringe (Monoject, Roehr Products Co., Inc., De Land, 
Fla.)  which had been rinsed with silicone oil  (SF 96-200,  General Electric Co.,  Waterford, 
N. Y.) was added to 0.1 ml of C'I esterase inhibitor or 0.005 ~  phosphate buffer in disposable 
glass or polystyrene tubes (internal diameter, 11 ram). The mixtures were inverted once over 
parafilm, and the clotting time of successive tubes was measured at 25°C. The interval elapsing 
until the contents of the third tube had clotted was recorded as the clotting time. 
The  effect  of C'I  esterase inhibitor  upon  the  clotting  time of plalelet-deftcient  plasma  was 
assessed by mixing 0.04 ml of inhibitor or 0.005 ~ phosphate buffer and 0.2 ml each of platelet- 
deficient citrated plasma and 0.025 ~  calcium chloride solution in polystyrene tubes (internal 
diameter, 8 man). The mixtures were incubated at 37°C and the interval which elapsed until 
clotting occurred was measured,  tilting the tubes once a  minute. 
The effect of C'1  esterase inhibitor  upon bovine thrombin  was tested by incubating 0.2 ml 
of the inhibitor or 0.005 ~ phosphate buffer with 0.1 ml of column-purified thrombin (40 NIH 
units/ml) for 5 rain at room temperature. 0.1 ml of partially purified human fibrinogen was 
then added to each tube and the clotting time measured at 37°C,  tilting the tubes continually. 
The effect of C'I esterase inhibitor  upon fi.brinolytic  activity and its evolution from plasma 
was measuxed in several ways. To test its effect upon the generation of fibrinolytic activity, 
0.2 ml of inhibitor (or 0.005  ~  phosphate buffer) was mixed with 1 ml of plasma and 0.5 ml 
kaolin  suspension  in  Lusteroid  (cellulose nitrate)  tubes.  The  mixtures  were  dialyzed  for 
60 rain against 2 liters of 0.01 N sodium acetate buffer (pH 5.2)  at room temperature, centri- 
fuged, and the supernatant solution discarded. The euglobulin precipitate, containing kaolin, 
was resuspended in 1 ml barbital saline buffer. To 0.2 ml. aliquots of the euglobulin-kaoliu 
suspension in polystyrene tubes (internal diameter, 8 ram) were added 0.06 ml C'1 esterase 
inhibitor to tubes originally containing 0.005 ~ phosphate buffer, and vice versa, 0.1 ml bovine 
fibrinogen, and 0.1 ml plasminogen-poor thrombin (50 NLU units/ml). After mixing, the tubes 
were incubated at 37°C. The clot lysis time was the interval which elapsed until there was 
complete dissolution of the fibrin. The technique used was designed to minimize dilution of 
the C'[ esterase inhibitor during the initial period of incubation. 
The effect of C'I esterase inhibitor upon fibrinolytic activity generated in a plasma-kaolin 
mixture was tested by a variation of the method just described. 2 ml of plasma, 1 ml of kaolin 
suspension, and 37 ml of 0.01  ~  sodium acetate buffer (pH 4.8) were incubated at 37°C  for 
60 rain in Lusteroid tubes (internal diameter 16 mm). After eentrifugation at 3000 rpm for 
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5 min, the supematant solution was discarded and the precipitate suspended in 2 ml barbital 
saline buffer. The suspension was again centrifuged, and the supernatant euglobulin solution, 
free of kaolin, removed. Fibrinolysis was measured in polystyrene tubes at 37°C in a mixture 
of 0.2 ml of euglobulin solution, 0.1 ml of C'I esterase inhibitor (or 0.005 M  phosphate buffer), 
0.1 ml bovine fibrinogen, and 0.1 ml plasminogen-poor bovine thrombin (20 NIH units/ml), 
and the clot lysis time measured. 
The effect of  C'I  esterase inl~bitor upon fibrinolysis was  also measured by incubating 
0.1 ml of inhibitor (or 0.005 ~  phosphate buffer), 0.1 ml of Cutter's spontaneously activated 
human plasmin, 0.2 ml bovine fibrinogen solution, and 0.1 ml plasminogen-poor bovine throm- 
bin (20 NIH units/ml) in polystyrene tubes (internal diameter 8 mm), and the interval until 
complete fibrinolysis took place was measured.  Similar experiments were performed with a 
second preparation of spontaneously activated human plasmin. 
In a third technique by which to assess the effect of C'I esterase inhibitor upon the fibrino- 
lytic activity of plasmin, 20 #i of mixtures of equal parts of Cutter's spontaneously activated 
human plasmin  (containing 1.3 Remmert and Cohen units/ml) and C'I esterase inhibitor, 
and dilutions of plasmin in 0.005 ~  phosphate buffer, were applied to the surface of fibrin 
plates 15 min after their preparation. After incubation for 20 hr at 37°C,  the area of lysis 
(calculated as the product of two perpendicular diameters of lysis) was measured. The loga- 
rithm of the area of lysis was proportional to the logarithm of the plasmin concentration ap- 
plied; the percentage inhibition of plasmin by C'I esterase inhibitor was obtained by interpo- 
lation. 
The effect of C'1 esterase inhibitor upon proteolysis  by plasmin was measured by a modifica- 
tion of the method of Remmert and Cohen (20, 23). 0.5 ml of spontaneously activated human 
plasmin and  0.5  ml  C'1  esterase inhibitor  (or  0.005  ~r phosphate buffer) were  incubated 
together at room temperature for 3 rain. i  ml of 0.15 ~  sodium phosphate buffer (pH 7.5)  and 
3.0 ml of  1.6%  casein were added,  and the mixture incubated at 37°C.  At 2  and 62 rain, 
2 ml aliquots were removed and mixed with 2 ml of 10% tridoroacetic acid. After 30 rain, 
the mixtures were centrifuged and the optical density of the dear supernatant solutions was 
read at 280 m# in a Beckman model DU spectrophotometer equipped with a Gllford absorb- 
ance meter. Optical density was converted to micrograms of tyrosine per milliliter by reference 
to  a  standard  tyrosine solution.  Similar  experiments were  performed with  streptokinase- 
activated human plasmin. 
The effect of C'I  eaterase inhibitor  upon  urokinase  was measured by incubating 0.25  ml 
each of urokinase solution (1000 CTA units/ml) and C'I esterase inhibitor (or 0.005 M phos- 
phate buffer) at room temperature for 10 min. A  volume of 2.5 ml  of  0.015  x, ALME was 
then added  to each tube and the mixture incubated at 37°C  for 60 rain. At the start and 
after 60 rain, 1 ml aliquots were removed and added to 0.5 ml 0.75  ~  perchloric acid in dis- 
posable glass tubes (internal diameter, 14 ram). The methyl alcohol liberated during incuba- 
tion was measured by Siegelman's (24) technique. 
The inhibition of C'lr by C'I esterase inhibitor  was detected in two ways. Inhibition of the 
capacity of Cqr to convert Cqs to C'I esterase was tested by incubating 0.25 ml Cqr with 
0.25 ml C'I esterase inhibitor and 0.50 ml sodium phosphate buffer (pH 7.4,  ionic strength 
0.15) for 10 rain at room temperature in disposable glass tubes (internal diameter, 11 ram). 
Next,  1 ml of C'ls was added, and the mixture incubated at 37°C for an additional 30 rain. 
The activation of C'ls was halted by the addition of 0.375 ml Liquoid, and 0.125 ml of 1 M 
ALTEE was added as substrate for the C'I esterase which had evolved. The mixtures were 
reincubated for 15 rain at 37°C; 1 ml aliquots were removed at the start and after 15 rain, 
and added to 1 ml of formaldehyde solution in the titration cup of a Radiometer model ABU 1 
automatic burette (Copenhagen, Denmark). The titratable acidity in the initial and 60 rain 
samples was measured by the addition of sufficient 0.05 s  sodium hydroxide with the auto- 
matic burette to bring the hydrogen ion concentration to a predetermined end point, usually 320  SERUM  ctl  ESTERASE ~sIB_rTOR 
7.4.  The  titrafions were performed  with  a  Radiometer TIT  11  titrator,  controlled  by  a 
Radiometer model 25  pH  meter. 
Inhibition of the esterolytic properties  of CIlr was  tested  by incubating  a  mixture of 
0.5 ml CIlr, 0.25 ml C~I esterase inhibitor, and 0.75 ml sodium phosphate buffer (pH 7.4, ionic 
strength  0.15)  in disposable  glass tubes  (internal diameter,  11  ram)  at room temperature 
for 15 rain.  1 ml of 0.015 M AAME was then added as substrate  and incubation continued 
for 50 rain at 370C. Immediately after the addition of this substrate,  and 60 rain later, 1 ml 
aliquots were removed and  added  to  1 ml of formaldehyde in the manner just described. 
The titratable acidity was then determined as in the measurement of C"I esterase activity. 
Vascular pcrme,~ili~y was measured by the method of Miles and  Wilhelm  (25).  0.1  ml 
aliquots of the solutions to be tested were injected intracutancously into the depilated backs 
of female albino guinea pigs, weighing 400-500 g which had been injected intravenously with 
1.2  ml/kg  of  body  weight  of  a  5%  solution  of  pontamine  sky  blue  6X  (E.  L 
du Pont de Nemours and Co., Wilmington, Del.) in 0.075 ~  sodium chloride solution. 15 rain 
after the last  injection, the  size  of the blue  spots which appeared  at the injected  sites,  a 
function  of  the  vascular  permeability-enhancing  properties  of  the  material  injected,  was 
estimated by averaging the largest diameter and its perpendicular. 
The effect of C~1 esterase inhibitor upon the evolution of permeability-enhancing activity 
in diluted human plasma was tested by incubating 0.3 ml of plasma (diluted 15-fold in barbital 
saline buffer  in silicone-coated Lusteroid  tubes),  0.2  ml of  C'1  esterase  inhibitor  (diluted 
serially in 0.005  M phosphate buffer) and 0.5 ml of eilagic acid solution at 37°C for 12 rain. 
At the end of this period, 0.2 ml of Ctl esterase inhibitor or phosphate buffer was added to 
appropriate  tubes and  the solutions tested by the method just described. The effect of the 
inhibitor was evaluated by comparison with the permeability-increasing properties  of the 
same plasma, diluted serially with barbital saline buffer and incubated  12 min with ellagic 
acid. The method used took advantage of the observation that ellagic acid, a known activator 
of Hageman  factor  (26),  induced  the  evolution of  the  permeability factor  designated  as 
PF/DIl (27). 
The eoolution of klninJike acg/~/ty was measured by the addition of 0.2 ml aliquots of test 
solutions to a bath of 8 ml of de ]alon's solution (28) at 29°C, in which was suspended a seg- 
meat of a horn of rat uterus. The uterus had been removed from a virgin rat (average weight 
about 350 g) which had been injected intraperitoneally 24 hr before with 10 #g of diethyl- 
stilbestrol/100 g of body weight. The effect of the test solution was compared with that of 
synthetic bradyk~nln, ~ diluted in 0.15 M sodium chloride solution in polystyrene tubes. The 
contraction of the uterus was measured essentially isotonically with a linear motion transducer, 
model ST-2, the transformer of which was supplied by an exciter-demodulator (Phipps and 
Bird,  Inc.,  Richmond,  Va.)  and  recorded  on  a  Servo-Recorder, model EUW-20A  (Heath 
Co., Benton Harbor, Mich.). 
The effect of C'1 esterase inhibitor upon the evolution of kln|n-like activity was measured 
in two ways. In one, plasma was treated with ellagic add to activate its Hageman factor. 
Hageman  factor is believed to  activate kallikrein from its precursor  in plasma,  and  this 
enzyme then releases polypeptide k]nlns from their precursor in plasma  (29). The test mix- 
tures consisted of 0.2 ml each of plasma and ellagic add  (or barbital saline buffer), 0.04 ml 
of 0.1 ~  trisodium ethylenedi-mlnetetraacetic acid (NavHEDTA, pH 7.0), 0.16 ml of barbital 
saline buffer, and 0.1 ml of C'1 esterase inhibitor  (or 0.005  M phosphate buffer). These mix- 
tures were incubated in polystyrene tubes (internal diameter, 8 ram) at 37°C for 30 rain, an 
additional 0.1 ml of C'1 esterase inhibitor (or 0.005 M phosphate buffer) was added to appro- 
priate tubes, and aliquots were then tested  for k{n]n-like activity by their effect upon the rat 
The gift of Sandoz Pharmaceuticals, Hanover, N. J. O. D. RATNOI~I~,  J. PENSKY, D. OGSTON, AND O. B. NAFI~  321 
uterus. The NasHEDTA served to inhibit kln~nases which would otherwise have inactivated 
the kinins as they formed  (30). 
The technique outlined did not distinguish clearly between an effect of C'I esterase in- 
hibitor upon the evolution of k~llikrein from  an effect upon kallikrein itself. To  test the 
effect of CPl esterase inhibitor upon preformed kalllkrein, 0.025 ml of C'I esterase inhibitor 
was incubated at room temperature for 5 rain with 0.05 ml of celite eluate, 0.05 ml 0.01 x¢ 
o-phenanthroline  0.05 ml hexadlmethrine bromide (1 mg/ml) and 0.175 ml barbital saline 
buffer in polystyrene tubes (internal diameter, 8 ram). After 5 rain, 0.15 ml of crude proklnln 
was added and incubation continued for 10 rain. Aliquots of 0.2 ml were  then tested for 
ldnln-like activity. Control experiments were  performed in which  C'1  esterase inhibitor 
was omitted or added just before testing upon the uterus. The celite eluate was a rich source 
of plasma kallikrein; hexadimethrine bromide was added, in great excess of the concentration 
needed, to inhibit any fresh activation of k~llikreinogen by Hageman factor, both of which 
may be present in celite  eluates (31). O-phenanthroline was used as an inhibitor  of kininase (32). 
TABLE I 
The Effect of C'1 Esterase Inhibitor on the Generation of Fib~inolyt~ Actldty 
Agent incubated  with plasma  and kaolin  Agent added  to euglobulln  before assay*  Clot lysls time 
1.  C'I esterase inhibitor (14 units/ml)  Buffer  19.5 
2.  Buffer  Buffer  18.5 
3.  Buffer  C'I esterase inhibitor (14 units/ml)  70.0 
* The generation system consisted of plasma, kaolin, and C'1 esterase inhibitor (or 0.005 
M phosphate buffer)  at pH 5.2, as described under Materials and Methods. After 60 rain, 
the insoluble euglobulin was sedimented, buffer or C'I esterase inhibitor was added, and the 
fibrinolytic activity of the mixture assayed. The concentrations of C'1 esterase inhibitor in 
tubes 1 and 3 are those in the generation and assay systems, respectively. 
l~ESULTS 
The Effect of C'I Esterase Inhibitor upon Blood Clolting.--In an earlier study, 
C'1 esterase inhibitor, at a  concentration of 1.6 units/ml, had no effect upon 
the esterolytic properties of bovine thrombin (4). Similarly, this agent did not 
delay the dotting of human fibrinogen by bovine thrombin. Thus,  the clotting 
time  of  a  mixture  of 0.2  ml fibrinogen  and  0.1  ml  column-purified bovine 
thrombln  (20 unlts/ml) was  13.8  sec in the presence of 0.1  ml 0.005 ~  phos- 
phate buffer, and 10.8 see in the presence of 0.1  ml C'I sterase inhibitor such 
that its concentration in the coagulation mixture was 20 units/ml. 
Thrombin is only one of many enzyme-like substances participating in blood 
dotting.  C'I  esterase inhibitor, at a  final concentration of 16.5  units/ml,  did 
not delay the coagulation of whole blood. Measured in glass tubes, the clotting 
time  of a  mixture  of blood and  C'1  esterase inhibitor or 0.005 ~  phosphate 
buffer was the same, namely, 14 min. Tested in polystyrene tubes, the dotting 
time was 65  min in the presence of C'I  esterase inhibitor and 85  min in the 
presence of buffer,  a  difference which  was probably not  significant but may 322  SERUN[  ctl  ESTERASE  INHIBITOR 
have reflected  contamination of the C'I  esterase  inhibitor preparation with 
traces of a procoagulant substance. 
Conceivably,  any inhibitory effect of C'1  esterase  inhibitor upon coagula- 
tion might have been masked by the presence of blood cells. But C'1 esterase 
inhibitor, at a  concentration in the mixture of 16.5 units/ml, had no effect 
upon  the recalcitied  clotting time of platelet-deficient plasma,  measured in 
polystyrene tubes. Thus,  the clotting time, in  the presence  of Ctl  esterase 
inhibitor, was  12 min, and, in the presence  of 0.005 M phosphate buffer,  11 
min. Under the conditions of this test,  the dotting time is sensitive  to the 
presence of small amounts of activated Hageman factor, which was apparently 
not inhibited by Cq esterase inhibitor. 
The Effect of CI1 Esterase Inhibitor  upon Components of the Plasma Fibrino- 
lyric System.--When human plasma euglobulin is incubated in the presence of 
TABLE  II 
The Effect  of C'I Esterase  Inhibflor  on Kaolin.Generated  Fibrinolytic  Activity 
Concentration of C'I esterase inhibitor*  Clot lysis time 
unils/rnl 
5.0 
2.5 
1.25 
0 
m~ 
21.0 
10.0 
7.5 
7.0 
* Fibrinolytic activity was generated by incubating plasma, kaolin,  and 0.01  M sodium 
acetate buffer for 60 rain (see Materials and Methods). The euglobulin fraction of plasma was 
dissolved in barbital saline buffer and separated from the kaolin. The effect of the addition 
of C'1 esterase inhibitor (or 0.005 ~  phosphate buffer) upon the fibrinolytic activity of the 
euglobulin fraction was then tested; the concentration of C'1 esterase inhibitor in the table 
is that in the final assay mixture. 
kaolin,  fibrinolytic activity evolves  (33, 34).  The  presence  of  C/1  esterase 
inhibitor, at a concentration of 14 units/ml, had no effect upon the generation 
of fibrinolytic activity (Table I). On the other hand, once fibrinolytic proper- 
ties had evolved,  C'1  esterase  inhibitor, at a  concentration of 2.5  units/ml, 
significantly delayed fibrinolysis (Tables I and II). 
The lysis time of fibrin clots prepared in the presence of spontaneously acti- 
vated human plasmin was lengthened when C'1 esterase  inhibitor was mixed 
with  the plasmin preparation before  its  incorporation into  the  clot  (Table 
III). This inhibitory activity was  greatly enhanced if the plasmin and C'1 
esterase  inhibitor were incubated together for 5 min before  the addition of 
fibrinogen  and thrombin. The same results  were obtained with plasmin pre- 
pared by two different methods. 
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tor and spontaneously activated human plasmin on fibrin plates revealed that 
C'1  esterase inhibitor at a  final concentration of 2.5  units/ml inhibited 77 % 
of the plasmin activity and at 5 units/ml inhibited 86 %. 
The fibrinolytic properties which  evolve in kaolin-treated euglobulin frac- 
TABLE III 
The Effed of C'I  Esterase Inhibitor upon the Fibrinolytic Activity  of Plasmin 
C'I esterase inhibitor 
unlts/ml 
0 
2 
5 
10 
20 
Clot lysis time, sec* 
Time of preincubation of C'I esterase inhibitor and plasmin 
0 rain  5 rain 
211 
237 
276 
318 
517 
220 
542 
5OOO 
* Lysis time of a clot formed by the addition of bovine fibrinogen and plasminogen-free 
thrombin to mixtures of spontaneously activated human plasmin and C'I esterase inhibitor 
(or 0.005 ~s phosphate buffer)  either immediately after they were mixed together or after 
their incubation together for 5 rain at room temperature. The plasmin contained 1.3 Remmert 
and Cohen  units/ml. The concentrations of C'I esterase inhibitor were  those in the final 
mixture. 
TABLE IV 
The Effect of C'I Esterase Inhibitor upon Hydrolysis of Casein by Plasmln* 
C'1 esterase inhibitor  Tyroslne-like material rdeased from casein 
uni~/ml 
0 
2.5 
5 
15 
I.tm&lml 
17 
10.5 
7 
2 
* Spontaneously active human plasmin,  C'I esterase inhibitor (or 0.005 ~r phosphate buf- 
fer), and casein were incubated at 37°C and the tyrosine-like  material released during diges- 
tion measured  (see Materials and Methods). The concentration of plasmin in the inhibitor- 
plasmin mixtures was 0.38 Remmert and Cohen unit/ml. The table records the  concentra- 
tion of C'I esterase inhibitor in the inhibitor-plasmin mixtures. 
tions are presumably attributable to plasmin, a  proteolytic enzyme of broad 
specificity. C~I  esterase  inhibitor,  at  concentrations  as low  as  2.5  units/ml, 
decreased the rate of hydrolysis of casein by spontaneously activated human 
plasmin (Table IV). Essentially similar results were obtained using two sources 
of spontaneously activated plasmin and using streptokinase-activated human 324  SERU'M Ctl  ESTERASE IN~I]J~ITOR 
plasmin; in the latter experiment, at a concentration of 2 units/nil,  C'I esterase 
inhibitor  significantly  inhibited  hydrolysis  of  casein  by  plasmin  (260  MSD 
units/ml). 
The inhibitor had no demonstrable activity against urokinase,  a  hydrolytic 
enzyme in human  urine  which  activates  plasminogen.  Under  the  conditions 
tested,  urokinase  released  114  #~t  of methyl  alcohol/ml  from  its  substrate, 
TABLE V 
The Effect of C'1 Esterase Inldbi$or upon C'lr 
Estem~ activity of add 
Test substance  liberated 
I. Hydrolysis of AAME* 
Buffer 
Cq esterase inhibitor, 0.5 unit/ml 
Cq esterase inhibitor, 0.25 unit/ml 
Cq esterase inhibitor, 0.125 unit/ml 
II. Hydrolysis of ALTEE, 
Buffer 
C'l esterase inhibitor added at start, 1.0 unit/ml 
C'I esterase inhibitor added at start, 0.5 unit/ml 
C'1 esterase inhibitor added at start, 0.25 unit/ml 
C'I esterase inhibitor added after Cq esterase evolved, 1.0 
uuit/ml 
Cq esterase inhibitor  added after Cq esterase evolved, 1.0 
unit/ml§ 
4.9 
2.3 
2.8 
4.3 
5.9 
1.7 
3.7 
5.9 
5.4 
1.7 
* Hydrolysis of AAME by mixtures of C'lr and C'I esterase inhibitor  or 0.005 ~ phos- 
phate  buffer  (see Materials  and Methods).  The concentration  of C'I esterase  inhibitor is 
that in the enzyme-substrate  mixture. 
:~ Hydrolysis of ALTEE by C'I esterase, evolved in a mixture  of C'ir and C'ls. C'l es- 
terase  inhibitor was added before the incubation  of C'lr and C'ls, or after the addition  of 
Liquoid,  used  to halt the interaction  of C'lr and C'ls. The concentration  of C'I esterase 
inhibitor  is that in the final mixture  (see Materials  and Methods). 
§ Liquoid omitted. 
N-acetyl-x-lysine methyl ester, while in the presence of C'1  esterase  inhibitor 
(33  units/ml  of  enzyme-substrate  mixture)  it  released  116  #~r.  Similarly, 
Donaldson (35), found that C'1 esterase inhibitor did not block the hydrolysis 
of ALTEE  which  was brought  about  by some,  but  not  all,  preparations  of 
urokinase. 
The Effect of Ctl Esterase Inhibitor upon Cqr.--The first component of com- 
plement,  Ctl,  can be dissociated  into  three  subcomponents,  C'lq,  Ctlr,  and 
Cqs  (3).  Preparations  containing Cqr in its active state convert Cqs to Crl 
esterase,  probably  enzymatically,  and  hydrolyze AAME,  among other  syn- O.  D.  RATNOF~', J.  PENSKY, D.  OGSTON, AND  O.  B.  NAI~  325 
thetic substrates  (36).  C'I esterase inhibitor blocked both of these reactions. 
The activation of C'ls was partially inhibited by as little as 0.7 units/ml, and 
the hydrolysis of AAME by as little as 0.25 units/ml (Table V). Measurement 
of the effect of C'lr upon C'ls was made possible by the fact that Liquoid, 
used to inactivate C'lr at the end of this reaction, appeared to block the sub- 
sequent action of C'I esterase inhibitor upon C'I esterase. 
The Effect of C'1 Esterase  Inhibitor on the Generation of Plasma Permeability 
TABLE VI 
TI~ Effect of C'1 Eaera~e Inhibitor upon Plasma PermeaMlity Aai~ty 
Mixture tested* 
Permeability 
activity 
Plasma  Diluent  Agent added after incubation 
1:50 
1:100 
1:50 
1:200 
1:800 
1:50 
1:50 
1:50 
1:50 
Buffer 
c~ 
EUagic acid 
cc  tc 
C'I esterase inhibitor (5.5 
units/ml)  and ellagic acid 
Ellagic acid 
tc  tc 
t~  tc 
tc  cc 
Buffer 
Buffer 
gc 
t¢ 
cc 
~t 
C'I esterase inhibitor (22 
units/ml) 
C'I esterase inhibitor (11 
units/ml) 
Cq esterase  inhibitor  (5.5 
units/ml) 
Buffer 
~t 
6.2 
4.3 
8.3 
8.2 
6.5 
4.2 
3.7 
6.0 
6.8 
4.8 
1.3 
* 1 ml mixtures, contMning plasma at the dilution noted, ellagic acid, and C'I esterase 
inhibitor (or buffer) were incubated at 37°C for 12 min. 0.2 ml of buffer or C'1 esterase in- 
hibitor was then added and 0.1 ml aliquots injected into each of four guinea pigs (see Mate- 
rials and Methods). The concentration of C'1 esterase inhibitor are those in the final mixture. 
:~ Mean diameter of blued spots. 
Aai~ty.--Kagan  and Becker (7, 8) reported that a partially purified fraction 
of plasma,  thought  to contain  the permeability enhancing factor designated 
as PF/DIl, was inhibited by relatively small amounts of C'I esterase inhibitor. 
In their studies,  the PF/DIl had apparently already been activated from its 
precursor in plasma. In the present study,  PF/DIl was generated in diluted 
plasma containing  ellagic acid,  an activator of Hageman factor. In the pres- 
ence of C'I esterase inhibitor, at a concentration of 5.5 units/ml, no detectable 
PF/DI1 was demonstrable after the mixture of diluted plasma and eUagic acid 
had incubated for 12 rain  (Table VI); the lesion evoked was no bigger than 
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C'1  esterase inhibitor was somewhat less effective in blocking the enhance- 
ment  of permeability activity if it was  added  to  the  mixture  of plasma  and 
ellagic acid after these had incubated for 12  min (Table VI). In other experi- 
ments,  the incubated mixture of diluted plasma and  ellagic acid was injected 
TABLE VII 
The  Effect  of  C'l  Esterase  Inhibitor  on  Plasma  Kallikrdn  Activity 
Mixture tested* 
Contraction 
of rat uterus 
Initial incubation mixture  Agent added before testing 
A.  Plasma +  buffer 
Plasma +  ellagic acid 
Plasma +  C'1 esterase inkibitor 
(15 units ml) +  ellagic acid 
Plasma +  ellagic acid 
Bradykinin,  50 ng 
"  30 ng 
"  10 ng 
B.  Celite eluate  +  buffer 
Celite eluate  +  C'I esterase in- 
hibitor (12 units  ml) 
Celite eluate  +  C'1 esterase in- 
hibitor (6 units  ml) 
Celite eluate  +  C'1 esterase in- 
hibitor (3 units  ml) 
Celite eluate  +  buffer 
Bradykinin,  20 ng 
"  10 ng 
"  5 ng 
Buffer 
gc 
C'1 esterase inhibitor  (15 units  ml) 
Prokinin 
I 
I 
Prokinin  +  C'1 esterase inhibitor 
(12 units ml) 
m~9~ 
2 
47 
17 
43 
60 
40 
15 
28 
2 
28 
38 
34 
22 
10 
* A. A mixture  of plasma,  ellagic acid, Na~HEDTA,  and either  C'I esterase  inhibitor  or 
0.005 ~  phosphate  buffer was incubated  for 30 rain  at 37°C (see Materials  and  Methods). 
Thereafter,  0.1 ml of C'1 esterase  inhibitor  or buffer was added  to appropriate  tubes.  0.2- 
ml aliquots were then added to a bath of de Jalon's solution in which was suspended a seg- 
ment of rat uterus.  The height of the contraction,  as amplified, is recorded in the table. 
B.  A mixture  of celite eluate, hexadimethrine  bromide, o-phenanthroline,  and either C'1 
esterase inhibitor or buffer was incubated at room temperature  for 5 min, after which prokinin 
was added as a substrate  of kallikrein, and the mixture incubated  at room temperature  for an 
additional  10 rain. C'1 esterase inhibitor  or buffer was then added appropriately,  and 0.2 ml 
aliquots tested  for muscle contracting  activity (see Materials  and Methods). 
into  sites  which  had  been  injected immediately before  with  C'I  esterase  in- 
hibitor or 0.005 ~  phosphate buffer.  Under these conditions,  the inhibition of 
permeability activity was less impressive than when the C'I esterase inhibitor 
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These experiments suggest that Ctl esterase inhibitor may have been effec- 
tive in blocking both the generation of PF/Dil and the permeability-enhancing 
effect of this agent. 
The Effect of C'1 Esterase Inhibitor on the Evolution of Kinin-Like Activity.  m 
Kagan and Becker (7, 8) also demonstrated that large amounts of C~I esterase 
inhibitor inactivated a fraction of plasma rich in kallikrein-like  activity. We 
have confirmed these observations by two techniques.  Ctl esterase inhibitor, 
at a concentration of 15 units/ml, partially inhibited the evolution or activity 
of kallikrein generated in a mixture of human plasma and ellagic acid, while 
at a concentration of 12 units/ml, it blocked the action of preformed kallikrein 
(Table VII).  When  C'1  esterase inhibitor  was added  after kinins  had  been 
allowed to generate, it was without effect. 
DISCUSSION 
C~1 esterase inhibitor was first detected in human serum by its capacity to 
inhibit  the esterolytic properties of C'1  esterase,  an agent derived from the 
Ct'ls fragment of the first component of complement (1). When partially puri- 
fied preparations of C'1 esterase inhibitor became available, it became appar- 
ent that it also inhibited chymotrypsin (4), plasma kaUikrein, and the permea- 
bility-enhancing  enzyme in  human  plasma  known as PF/Dil  (7,  8).  These 
observations suggested that  C~I  esterase inhibitor  might  well  be an  inhibi- 
tor with broader properties than had been thought originally. 
Since these earlier reports, considerable progress has been made toward the 
purification  of  C~I  esterase  inhibitor.  The  preparations used  in the present 
study were purified  1700 times compared with the serum from which it was 
prepared. The inhibitory properties of C~1 esterase against PF/Dil and plasma 
kaUikrein  have been confirmed with  these highly purified preparations.  C~1 
esterase inhibitor blocked both the generation of PF/Dil and, less effectively, 
its action in  enhancing  vascular permeability in  guinea pig skin.  Moreover, 
C~1 esterase inhibitor blocked the generation  of kinin-like  properties in mix- 
tures of plasma kallikrein and kininogen. 
C~I esterase inhibitor decreased both the fibrinolytic and caseinolytic prop° 
erties of human plasmin, while it had no effect upon the generation of plasmin 
in kaolin-treated euglobulin fractions of plasma nor upon urokinase,  an acti- 
vator of plasminogen  (the  precursor  of plasmin)  found in human  urine.  In 
contrast, in an earlier study, 1.6 units of C~I esterase inhibitor did not block 
the  hydrolysis  of  p-toluenesulfonyl-L-arginine  methyl  ester  by  3000  MSD 
units of plasmin (4). The difference in results may have been due both to the 
higher concentrations of plasmin used in the esterolytic assay and to the lower 
concentration  of Ctl  esterase inhibitor.  Alternatively,  Crl  esterase inhibitor 
may block a site needed for the proteolytic activity of plasmin, but not for its 
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Human plasma contains several different agents capable of inhibiting plas- 
min (37--40). We are unfamiliar with any definitive study clarifying the nature 
of these various inhibitors.  Thus,  inhibitory properties have been attributed 
to a  heat-stable ~x2-globulin fraction of plasma  (39).  In  another  study,  two 
heat-stable inhibitors  were described,  one of which was inactivated  by am- 
monia,  hydrazine,  and  certain  primary  amines,  and  one  of  which  resisted 
these agents  (38).  Inhibitory properties were also found in a  heat-labile od- 
globulin fraction (40). Moreover, treatment of plasma with chloroform dimin- 
ishes its inhibitory activity against plasmin (41), but the nature of the agent 
affected by this  treatment  is  not known.  Notably,  plasma,  extracted  with 
another organic solvent, ether, lacks CI1 esterase inhibitory properties (42). 
Cq esterase inhibitor is rapidly inactivated at 56°C (1, 3), but it is an ~x2- 
globulin. Its identity with previously described inhibitors of plasmin is there- 
fore not yet clear.  Whether  the plasmin inhibitory property of CJ1  esterase 
inhibitor is of biologic importance is still to be learned, but the concentrations 
which blocked caseinolysis were less than those found in normal human plasma 
(5).  Further  experiments  are  needed  to  determine  the  role  of  Cq  esterase 
inhibitor  in  the physiologic activity of plasmin,  and  the identity of this in- 
hibitor with others described in plasma. 
The  possibility that  Cq  esterase inhibitor  blocked the generation  of Cq 
esterase in plasma euglobulin fractions was raised in earlier studies, but the 
mechanisms involved were unclear  (43, 44). In the test tube, C'1  esterase is 
generated from the Cqs fragment of the CI1 molecule through the enzymatic 
action of a  second fragment,  the C'lr subcomponent. This action of CPlr  is 
apparently enzymatic (36). In the present experiments, the role of C'I esterase 
inhibitor was studied by taking advantage of the inhibition of Cqr by Liquoid. 
Addition of this agent to mixtures of Cqr and Cqs allowed the measurement 
of any CPl esterase which may have generated while  preventing  further  evo- 
lution of this enzyme during the assay. Under these circumstances, the forma- 
tion of Cq esterase in mixtures of Cqr and Cqs was strikingly inhibited by 
the presence of Cq esterase inhibitor. Preparations of C~lr also possess estero- 
lytic properties (36). Proof that the esterase in preparations of Cqr is identical 
with this subcomponent of complement awaits its further purification,  but it is 
noteworthy  that  the  hydrolysis  of  its  most  unique  substrate,  N-acetyl-L- 
arginine  methyl ester, was readily inhibited by C'I esterase inhibitor. 
SUMMARY 
The fraction of human serum designated as Cq esterase inhibitor is known 
to inhibit the action of Cq esterase, a plasma kallikrein,  and PF/Dil, an en- 
zyme in plasma  enhancing  cutaneous vascular permeability.  In  the present 
study,  C~I esterase inhibitor has been found to block the actions of plasmin 
and  the Cqr  subcomponent of the first component  of complement,  and  to O.  D.  RATNOFF, J.  PENSKY, D.  OGSTON, AND G.  B.  NAFF  329 
retard  the  generation  of PF/Dil.  No  inhibition  of blood  clotting  or  of  the 
generation of plasmin was demonstrable. 
These experiments would not have been possible without  the expert aid of Mrs. Edgar 
Stone, Mr. Paul Cox, and Mr.  Stanford Williams. 
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